Biocon has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) from the U.S. Food and Drug Administration (USFDA), for its API facility (Site 5), located at Visakhapatnam, Andhra Pradesh. This is based on a GMP inspection conducted by the agency between June 17 and June 21, 2024. Biocon remains committed to Quality, Safety & Efficacy of the products manufactured.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.